Core Insights - Aligos Therapeutics, Inc. is set to present data from its Phase 1 monotherapy study of ALG-000184 at The Liver Meeting 2025, highlighting its focus on therapies for liver and viral diseases [1][6] - The company will showcase eight presentations, including an oral presentation on ALG-000184, a novel capsid assembly modulator for chronic hepatitis B virus (HBV) infection [1][2] Presentation Details - The oral presentation titled "Oral Once-Daily 300 mg ALG-000184, a Novel Capsid Assembly Modulator Demonstrates Potent Suppression of HBV DNA in Treatment-Naive or Currently-Not-Treated Subjects with Chronic HBV" will be presented by Professor Man-Fung Yuen on November 9, 2025 [2] - A poster presentation will discuss the sustained reduction of HBV antigen levels during the 8-week follow-up period in treatment-naive or currently-not-treated HBeAg-positive subjects after 96 weeks of 300 mg ALG-000184 [3] - Additional poster presentations will cover various aspects of capsid assembly modulators, including ALG-001075's prevention of cccDNA formation and HBV DNA integration [3][4][5] Company Overview - Aligos Therapeutics is a clinical-stage biotechnology company dedicated to developing best-in-class therapies for liver and viral diseases, with a focus on chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis [6]